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Strategies that prevent chronic Pseudomonas aeruginosa infection in Cystic Fibrosis
patients are desirable. Vaccination would be a sensible approach. A meaningful
animal infection model that represents protection at the airway mucosa surface is
still lacking, since present models tend to mimic chronic or lethal airway infection
with high doses of P. aeruginosa. Consequently, we pursue a model of low dose nasal
inoculation and longitudinal investigation of physiologic parameters to monitor the
onset of infection.
Using head-out spirometry we are able to monitor P. aeruginosa infections as low as
5×104 CFU PA14 in C57BL/6 mice. 18 relevant respiratory parameters including
respiration rate, tidal volume and midtidal expiratory ﬂow at 50% are analyzed
over a course of 8 days post infection. One of the most sensitive parameters is
tidal volume which dropped by 62% within 4 hours post infection with recovery
after 7 days. A clear dose-dependency could be monitored. Additionally a number
of physiological parameters are checked to monitor the state of infection. In the
near future the protectivity of a vaccine against P.aeruginosa will be investigated in
C57BL/6 and isogenic CFTR-deﬁcient mice.
Additionally, to monitor the infection in vivo, bioluminescent pseudomonads,
including the clinically important strains PAO1 and TB were developed using
transposon mutagenesis (mini-ctx-lux). First infection experiments in C57BL/6 mice
showed that a lung infection with bioluminescent pseudomonads can be monitored
until clearance after 24 hours.
We conclude that this infection model holds promise for assessment of airway
pathology which better mimicks the clinical situation.
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Introduction: Longitudinal data on genotypes of PA strains after eradication
treatment are limited. We followed CF patients after a ﬁrst ever PA isolate and
evaluated the PA free time period after eradication therapy and the efﬁcacy of this
treatment relying on comparison of the genotypes of subsequent PA isolates.
Methods: From June 2002 till December 2008 sputa or nasopharyngeal aspirates
were cultured prospectively from 41 CF patients with a ﬁrst ever PA isolate.
Eradication treatment consisted of oral ciproﬂoxacin and inhaled tobramycin or
colimycin for 3 months Genotyping of PA was carried out by RAPD-analysis.
Results: Eradication treatment was successful in 34(83%) patients. Twenty out of
these (59%) reacquired PA after a median period of 12 months, with 4 patients
becoming chronically colonized after a median time of 13 months. At present,
14 patients (34%) remain PA free after a median follow-up period of 3 year
2 months.
Fifteen of the 27 patients (55%) with at least a second isolate showed an identical
PA genotype. Patients becoming chronicically colonized during the study period
had a signiﬁcantly shorter PA free interval between the ﬁrst ever and second isolate
compared to not chronically colonized patients with at least 2 isolates (p 0.041).
Conclusion: Our ﬁndings of eradication success and median time to recurrence
after a ﬁrst positive PA culture were comparable to other studies. More long lasting
eradication however was achieved. An identical PA in the second positive culture
and a short PA free interval are ominous signs of impending chronic colonization.
Supported by: Belgian Cystic Fibrosis Association.
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Background: Eradication of early Pa infection is now standard practice, although
many different protocols are used and controversy remains over long term effects.
Objective: To determine the efﬁcacy of a Pa eradication protocol in children <5 yrs.
Methods: Data on Pa acquisition ( 1000 CFU/mL for BAL group; +ve oropha-
ryngeal specimen for std group) were collected prospectively as part of an ongoing
multicentre RCT designed to examine BAL-directed therapy in children diagnosed
with CF by newborn screening. 168 infants were randomized at a mean of 3.6 (SD
1.6) mths of age (84 BAL, 84 Std therapy). Final outcomes for all children at 5 yrs
included BAL. A standardized Pa eradication protocol was used across all sites for
both arms of the study: 2 wks IV anti-pseudomonal antibiotics then 1 mth oral
ciproﬂoxacin + 2 mths nebulised TOBI®.
Results: By 31/12/07, 85/168 patients had >1 episodes of Pa eradication treatment.
51 children were reinfected (mean 402 (range 35–959) days between episodes).
Average age of Pa acquisition was 2 (SD 1.3) yrs. After a single eradication
treatment, Pa was cleared 93% of the time. 10/100 children were Pa +ve at end
of study BAL at age 5 yrs. A. fumigatus and S. maltophilia were more frequently
cultured from the end of study BAL if eradication treatment had been given (14/56
v 1/44 p = 0.002; 6/56 v 0/44 p = 0.033 respectively).
Conclusions: Early, aggressive treatment is successful at eradicating Pa but may
be associated with emergence of A. fumigatus and S. maltophilia.
Supported by: NHMRC and RCHF Brisbane, TOBI® supplied by Novartis Phar-
maceuticals Corporation.
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Eradication of new new isolates of P aeruginosa(PA) is a key part of management
in CF. However most of the data on eradication therapy relates to children. In
this study we report the outcomes of eradication therapy in an adult population.
Adults with CF and a ﬁrst sputum isolate of PA from 1999 to 2007 were studied.
The mean age of this group was 30 years and 59% were male. Seventeen patients
had a new isolate of PA during this period of study. Nine patients were treated
with oral Ciproﬂoxacin (Cip) and nebulised Colomycin (Col) for 3 months, four
were treated with intravenous anti-pseudomonal antibiotics for 14 days and then
received 3 months of Col. A further four patients received other combinations of
oral Cip and nebulised antibiotics. In 11(65%) patients successful eradication was
achieved with a negative sputum culture within 6 weeks of commencing treatment
and at least 3 negative sputum cultures in the subsequent 6 months with the ﬁrst
treatment. In the six patients who continued to isolate PA after 4 weeks, second
line therapy was initiated in 4 cases using intravenous antibiotics and in 2 nebulised
Tobramycin. Following this, in a further 3 patients PA was successfully eradicated.
All patients who had successful eradication had negitive sputum cultures by 6 weeks
and remained negitive for 12 months. The median time to eradication was 1 month
and median time to a new isolate of P. aeruginosa was 31 months. There was no
signiﬁcant change in FEV1 demonstrated at 12 months. Conclusion: Eradication of
P. aeruginosa was successful in 84% of all patients isolating P. aeruginosa infection.
Aggressive treatment of new infection of P. aeruginosa in adults is successful in the
majority of patients and is of similar efﬁcacy to the reported success in paediatric
populations.
